Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:20 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $162.3M (7973.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 11, 2025 | Jan 8, 2024 | Feb 7, 2023 | Jan 10, 2022 |
| Revenue | $2.04M | $6.24M | – | – | – |
| Operating expenses | $180.0M | $108.1M | $51.0M | $80.9M | $74.7M |
| Research and development | $145.6M | $83.1M | $32.8M | $55.1M | $46.8M |
| Selling, general and administrative | $34.3M | $25.0M | $18.2M | $25.8M | $27.9M |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$80.9M | -$74.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$76.5M | -$71.1M |
| EPS, basic | $-4.20 | $-2.55 | $-8.45 | $-1.29 | $-1.29 |
| EPS, diluted | $-4.20 | $-2.55 | $-8.45 | $-1.29 | $-1.29 |
| Weighted shares, basic | 38.6M | 33.3M | 5.15M | 59.4M | 54.9M |
| Weighted shares, diluted | 38.6M | 33.3M | 5.15M | 59.4M | 54.9M |
| Margins and growth | |||||
| Operating margin | -8739.3% | -1633.7% | – | – | – |
| Net margin | -7973.3% | -1362.8% | – | – | – |
| Revenue growth, year over year | −67.3% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 11, 2025 | Jan 8, 2024 | Feb 7, 2023 | Jan 10, 2022 |
| Cash and equivalents | $51.1M | $22.8M | $132.3M | $57.6M | $131.7M |
| Short-term investments | $353.2M | $252.4M | $41.4M | $54.4M | $45.3M |
| Accounts receivable | $52.0K | $807.0K | $294.0K | – | – |
| Total current assets | $409.4M | $280.9M | $177.5M | $115.6M | $180.7M |
| Property, plant and equipment | $296.0K | $194.0K | $185.0K | $6.09M | $7.46M |
| Total assets | $530.9M | $374.0M | $179.4M | $146.6M | $189.9M |
| Accounts payable | $9.72M | $4.58M | $2.61M | $2.45M | $3.04M |
| Total current liabilities | $30.7M | $18.5M | $9.63M | $14.5M | $10.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $40.7M | $17.3M |
| Shareholders' equity | $493.4M | $352.5M | $168.9M | $106.0M | $172.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Mar 11, 2025 | Jan 8, 2024 | Feb 7, 2023 | Jan 10, 2022 |
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$67.1M | -$59.5M |
| Capital expenditures | $213.0K | $105.0K | $110.0K | $314.0K | $1.26M |
| Free cash flow | -$129.3M | -$78.3M | -$37.0M | -$67.4M | -$60.8M |
| Depreciation and amortization | – | – | – | $1.93M | $2.02M |
| Stock-based compensation | $22.8M | $12.9M | $2.90M | $7.02M | $10.3M |
| Investing cash flow | -$122.8M | -$286.8M | $20.3M | -$9.81M | $43.4M |
| Financing cash flow | $280.1M | $255.6M | $133.6M | $2.88M | $89.6M |
| Net change in cash | $28.2M | -$109.4M | $117.0M | -$74.0M | $73.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1119.5% | 206.8% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 56.3M | +31.3% | SEC |
| Aug 3, 2026 | 55.9M | +73.8% | SEC |
| May 1, 2026 | 54.7M | +70.0% | SEC |
| Mar 4, 2026 | 44.5M | +38.4% | SEC |
| Nov 3, 2025 | 42.9M | +44.9% | SEC |
| Aug 6, 2025 | 32.2M | +9.7% | SEC |
| May 7, 2025 | 32.2M | +9.6% | SEC |
| Mar 7, 2025 | 32.1M | +9.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-16 in Q3 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.